Sarepta Therapeutics Inc (SRPT) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised ...

Negative Points

• Total product revenues decreased 13% year-over-year in Q3 and 34% for the first nine months of 2026, driven by lower Elevidys sales.

• Sarepta Therapeutics Inc ( NASDAQ:SRPT ) decided not to resume enrollment in the ENVISION study for non-ambulatory patients due to operational and technical barriers after a prolonged hold, delaying potential label expansion.

• The company recorded $52 million in take-or-pay charges related to non-cancelable manufacturing obligations for Elevidys, which significantly impacted gross margins (59% in Q3).

• Elevidys faces inherent quarter-to-quarter variability as a one-time gene therapy, and revenue growth reacceleration timing remains uncertain, with no specific guidance on when growth will return.

• Potential competition looms for Exondys 51 with a competitor's exon 51 skipper expected to receive FDA approval in January 2027, which could impact market share later in 2027.

Q & A Highlights

Q: With ongoing patient and physician education initiatives for Elevidys, what is resonating and what needs more work? A: CEO Michael Severino said the long-term data, particularly in the 8-to-12 population, is resonating most, as it re-centers the benefit-risk discussion around a progressive and ultimately lethal disease. Chief Commercial Officer Patrick Moss added that changing prescribing behavior takes time and repetition, and the expanded sales team is now meeting many physicians multiple times to walk through the data in depth.

Q: How does terminating the ENVISION study impact the potential return of Elevidys in the non-ambulatory market, and what splicing improvement would you consider a success in DM1 given the Novartis failure? A: Severino said ENVISION was never part of the plan to return to the non-ambulatory population; the central piece is Endeavor Cohort 8, which studies sirolimus to improve benefit-risk, with data expected to inform FDA discussions in Q1 2027. On DM1, he said more splicing correction is better, that Novartis's roughly 10%-15% was likely insufficient, and that Sarepta aims to be well above that range, starting with robust DMPK knockdown.

Q: What gives you confidence to move the siRNAs into Phase III and ramp up before fully unblinding, and could you still pursue accelerated approval even if that path is not available to others? A: Severino cited a constellation of evidence strong preclinical data, single ascending dose data showing high muscle concentrations, and expected robust knockdown translating to downstream effects as the basis for rapid preparation. He added that accelerated approval should be on the table for both DM1 and FSHD because the pathway depends on the strength of the data, which Sarepta expects to have.

Q: On safety for the DM1 siRNA, what adverse events are you watching for, and could the integrin-targeting delivery system raise respiratory or cardiovascular signals? A: Severino said the preclinical and single ascending dose safety profile has been very favorable with no dose-limiting toxicities or identified adverse events of interest. He noted there is no transferrin receptor component, so anemia is not expected, and that intermittent exposure via integrin targeting as a delivery vehicle differs from prolonged alpha-V-beta-6 suppression, so pulmonary effects are not anticipated.

Q: As you move quickly into registrational studies for DM1 and FSHD, how are you thinking about dose selection and the timeline to FDA meetings? A: Severino said greater knockdown is better, so Sarepta will take forward the highest tolerable dose with the best knockdown, noting higher-dose cohorts in both programs will read out in early 2027 and could ultimately be the selected dose. Chief Medical Officer James Richardson added that combining the upcoming readouts should allow dose selection and regulatory discussions in the new year.

Q: What needs to be done before releasing the upcoming MAD data, are there gating items to pivotal trial start, and how does Novartis's Harbor miss shape your pivotal DM1 design? A: CSO Louise Rodino-Klapac said the remaining work is standard end-of-study data transfer, cleaning, QC, and analysis. Severino said Harbor's full data, expected at a spring meeting, will clarify whether patient selection, variability, or insufficient knockdown drove the miss, and that Sarepta is not locked into any design and retains flexibility across accelerated and full approval approaches.

Q: Given Sarepta's mixed history with randomized controlled trials in muscle disease, what clinical endpoint and timeframe would you use for a pivotal DM1 study? A: Severino said the higher the knockdown and splicing correction, the greater the ability to show improvement on any clearly disease-related endpoint. Richardson emphasized that the key learning is not the endpoint itself but the population tested and the duration of testing, and that Sarepta is reviewing natural history and external data with KOLs to identify the most responsive endpoints, population, and time period.

Q: After nearly 100 days, what is your view of Sarepta's trial design and execution capabilities, and what would you change to give DM1 and FSHD the best chance of success? A: Severino, drawing on development experience at Amgen and AbbVie, said the most important factor is achieving the largest possible effect size, which is why robust DMPK and DUX4 knockdown is critical. He added that experienced clinical sites, consistent endpoint administration, and quality data are essential, and that Sarepta's study design and statistical capabilities are as good as anywhere, giving him confidence in the siRNA programs.

Q: For FSHD, why the emphasis on concordance across PD markers, and is the signal-to-noise hurdle higher than in DM1? Will you report vHOT for DM1? A: Rodino-Klapac said FSHD allows circulating biomarkers to supplement single-timepoint biopsy data, so Sarepta is looking for consistency across PK, DUX4 target genes, and circulating biomarkers. Severino confirmed vHOT and other functional measures will be reported for DM1 but cautioned the cohorts are very small for functional endpoints, so investors should not over-index on early functional data.

Q: How do you view potential competition for Exondys 51 if a competitor exon 51 skipper is approved at its January PDUFA date, and what is the base case for restoring a non-ambulatory label for Elevidys after Cohort 8 data? A: Severino said Sarepta assumes Dyne will be approved in January 2027 but believes its long safety track record and real-world evidence position it well, and that reimbursement setup typically takes months, so wholesale switching of stable patients is unlikely early, with impact more likely toward the back end of 2027. On non-ambulatory Elevidys, he said Sarepta plans to approach FDA toward the end of Q1 2027 with 12-week Cohort 8 safety data to inform next steps.

Q: What are you targeting for HTT knockdown with SRP-105 in Huntington's, and how confident are you in brain distribution and safety? A: Severino said preclinical data clearly show the therapy crosses the blood-brain barrier and reaches deep brain nuclei needed for clinical benefit, and that Arrowhead has shown blood-brain barrier crossing with the same delivery technology. He said Sarepta is aiming for very substantial knockdown and expects proof-of-biology data around mid-2027, with Richardson noting

For the complete transcript of the earnings call, please refer to the full earnings call transcript .